Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Gregory Day

Neurology Jacksonville, FL Medical Doctor

NPI 1962880757 CMS profile 1372915

4500 San Pablo Rd S, Jacksonville, FL 32224

Open in the dashboard

General payments

$6,168

13 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$172,416 paid to institutions, not to them · program year 2019

Through program year 2025, Gregory Day of Jacksonville, FL is reported in the CMS Open Payments database as having received $6,168 across 13 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $172,416 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 68th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $132 1
2024 General $206 2
2023 General $1,662 7
2022 General $4,168 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Day
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Gregory Day were reported at $132. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Gregory Day Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $4,168 $442 $103–$2,388 $149
2023 $1,662 $464 $119–$2,312 $160
2024 $206 $468 $119–$2,323 $164
2025 $132 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Eli Lilly and Company $5,352 5 payments
  2. UCB, Inc. $296 3 payments
  3. Horizon Therapeutics plc $272 3 payments
  4. TG Therapeutics, Inc. $132 1 payment
  5. Amgen Inc. $116 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,988 1 payment
  2. Travel and Lodging $1,269 3 payments
  3. Food and Beverage $911 9 payments
Products named General payments · program years 2022–2025
  1. UPLIZNA Uplizna $272 3 payments
  2. BRIUMVI $132 1 payment
  3. UPLIZNA Inflammation/Rare Disease $116 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

223

Median for Neurology: 833

Drug cost

$9,875

Median for Neurology: $202,670

Branded share of claims

0%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rivastigmine Generic 25 $5,204
Donepezil Hcl Generic 134 $2,035
Mirtazapine Generic 21 $1,225
Memantine Hcl Generic 16 $871
Quetiapine Fumarate Generic 14 $398
Escitalopram Oxalate Generic 13 $143

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$32,415

Medicare's payments for the services billed

Medicare patients

207

Average age 77

Services billed

340

101 women, 106 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Alzheimer's or dementia 71%
High blood pressure 69%
Arthritis 45%
Depression 38%
Ischemic heart disease 32%
Chronic kidney disease 26%
Cancer 25%
Diabetes 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record